A Single Gut Bacterium Triggers Immune Attacks on Endometrial Cancer Cells

Endometrial cancer is the fourth most common cancer among women in the United States, yet for patients who relapse or develop metastatic disease, treatment options remain sharply limited. A new study published May 19, 2026 in the journal Microbiome offers an unexpected route forward: a soil-derived bacterium called Bacillus megaterium KCTC 3007, found naturally in endometrial tissue, appears to prime the immune system to recognize and kill cancer cells. The researchers describe it as the first bacterium identified at the single-strain level to systematically activate anticancer immunity in endometrial cancer.

Bacillus megaterium KCTC 3007 Suppresses Endometrial Cancer Recurrence

The core finding is both specific and striking. Patients with higher tissue abundance of Bacillus megaterium showed prolonged recurrence-free survival compared to patients with lower abundance. That correlation held up across a cohort of 60 endometrial cancer patients and 18 benign controls recruited at Seoul National University Hospital. The bacterium's presence in tissue also positively correlated with elevated serum levels of trimethylamine N-oxide, a metabolite known by its abbreviation TMAO. The team, led by Hansoo Park and Maria Lee from GIST and Seoul National University, traced the mechanism step by step: B. megaterium carries the cutC gene, which drives choline metabolism and leads directly to TMAO production. TMAO then activates type I interferon signaling, a molecular alarm system that mobilizes T cells to attack tumors.

In cell culture experiments, B. megaterium inhibited endometrial cancer cell proliferation by expanding CD8+ T cell populations, the cytotoxic immune cells that physically destroy cancer cells, and by increasing direct contact between immune cells and tumor cells. When TMAO was administered alone, it replicated those effects: it boosted CD8+ T cell responses and, notably, preferentially induced pyroptotic cell death in cancer cells. Pyroptosis is a form of inflammatory cell death that can amplify immune signaling, potentially creating a self-reinforcing immune response.

Why These Results Matter for Women With Recurrent Endometrial Cancer

Endometrial cancer's rising incidence, especially in high-income countries, has not been matched by equivalent advances in treatment for recurrent disease. Immune checkpoint inhibitors have shown promise in a subset of patients, but many tumors do not respond. As Maria Lee noted, the study offers "a novel microbial perspective to the question: why do some patients experience recurrence while others do not?" The bacterium-to-metabolite-to-interferon pathway identified here suggests that the immunological fate of an endometrial tumor may partly depend on which bacteria happen to inhabit the tissue. Research into the role of the microbiome in endometrial cancer pathogenesis has accelerated in recent years, with growing evidence that both gut and local endometrial microbiomes influence inflammation, estrogen metabolism, and immune responses. This study sharpens that picture considerably by pinning the effect to a single strain and a single metabolite.

Multi-Omics Methodology Linking Microbes, Metabolites, and Host Immunity

What separates this study from earlier correlational microbiome work is its layered evidence design. The team applied metatranscriptomics to profile active tissue-resident bacteria rather than simply cataloging DNA. They ran transcriptomics to capture host gene expression changes in the same tissue, performed serum metabolomics on all 78 participants to identify microbial-metabolite associations, and confirmed findings with in vitro co-culture experiments using peripheral blood mononuclear cells and cancer cell lines alongside RNA sequencing and live cell imaging. Tracking bacteria, metabolites, and host immune responses within the same patient cohort at once is rare. Hansoo Park described it as "the first case to systematically identify, at the single-strain level, a pathway through which anti-cancer immunity is induced" in this way. Prior reviews have noted how endometrial microbiome and immune system interactions were poorly characterized at the mechanistic level; this study fills a significant part of that gap.

TMAO's Dual Reputation and What This Study Clarifies

TMAO carries complicated baggage in the biomedical literature. A well-publicized line of research associates high circulating TMAO with elevated cardiovascular risk, framing it as a harmful byproduct of gut bacterial metabolism of red meat and eggs. The current study does not dispute that association but situates TMAO in a different context: at the tumor-immune interface in endometrial tissue, TMAO appears to function as an immune activator rather than a vascular threat. The researchers are explicit that their findings are specific to endometrial cancer and to the signaling environment created by B. megaterium. That context-dependence matters for how any future therapeutic application would need to be framed and targeted.

Clinical Translation and the Road From Strain to Treatment

For all its mechanistic clarity, the study is still at an early, preclinical stage. The authors flag that exploratory findings on other bacterial strains, including Cupriavidus taiwanensis and Marinomonas primoryensis linked to poor prognosis, require caution because of limited subgroup sizes. Moving from a cell-culture result to a validated clinical intervention involves hurdles that have stalled many promising microbiome findings before: strain-specific variability across patients, dosing and delivery optimization, and the absence of large-scale human trials. A recent review on challenges in microbiome-based cancer therapy catalogued exactly these obstacles as the central bottleneck between mechanistic insights and clinical practice. Hansoo Park's team has proposed microbe-based combination therapy as a strategy for patients whose tumors respond poorly to conventional drugs or immune checkpoint inhibitors, but the path from proposal to protocol will require prospective trials. Researchers working on future microbiome research directions in endometrial cancer have pointed to the need for studies that link specific bacterial strains and their metabolites to immunotherapy outcomes. The B. megaterium KCTC 3007 pathway, with its defined genetic mechanism, measurable serum metabolite, and immune cell readout, gives those future trials a concrete target to test.